Dendropanax morbiferus extract,
does it really help with Relief of hangover and improvement of alcohol-related liver injury and liver enzymes?
research showsThe claim that Dendropanax morbiferus extract relieves hangover and improves alcohol-related liver injury or liver enzymes in humans is rated D. Leaf extracts improved AST, ALT, histologic injury, blood alcohol and acetaldehyde, and antioxidant enzymes in alcohol-fed rats and showed protective signals in HepG2 or hepatocyte models. These are cell and animal experiments. Human randomized trials exist for other efficacy axes such as metabolic syndrome, heavy metals, and blood pressure, but no direct trial was identified for post-drinking hangover, alcohol-related liver disease, or sustained liver-enzyme improvement. As with the preceding Acer tegmentosum verdict 870, actual preclinical liver evidence makes D more accurate than a question mark.
ads claimMarketing converts lower AST and ALT in rats, altered antioxidant enzymes, and reduced cellular lipid accumulation into human hangover relief, liver detoxification, and normalized liver tests. Hangover symptoms, blood-alcohol clearance, prevention of acute liver injury, and treatment of chronic alcohol-related liver disease are distinct clinical claims.
Useful facts when choosing a product
- Dendropanax morbiferus is an evergreen member of the Araliaceae family whose leaves, stems, and bark are used; publications also spell the species name Dendropanax morbifera.
- Plant part, harvest season, water or ethanol solvent, and marker compounds differ across studies, so preclinical results cannot be applied uniformly to every tea, concentrate, or capsule.
- The existence of small human trials for metabolic syndrome or antioxidant outcomes does not establish efficacy for hangover or alcohol-related liver injury, and food or regulatory recognition does not guarantee an effect for every product.
- Traditional food use and preclinical toxicology provide some reassurance, but human long-term use, use in liver disease, pregnancy or breastfeeding, medicine combinations, and product-specific purity and contamination remain inadequately studied.
What the research actually shows
Bae and colleagues exposed hepatocytes and rats to ethanol, administered an aqueous Dendropanax leaf extract, and measured viability, reactive oxygen species, serum AST and ALT, malondialdehyde, glutathione and antioxidant enzymes, CYP2E1, and blood alcohol. Eom and colleagues coadministered aqueous or ethanol leaf extracts to alcohol-fed rats and assessed liver histology, AST and ALT, alcohol and acetaldehyde, antioxidant enzymes, and gut microbiota. The findings were positive, but there were zero human participants. A 74-person metabolic-syndrome trial and a 60-person heavy-metal and antioxidant trial do exist, but neither tested alcohol, hangover, or alcohol-related liver disease and therefore does not count as human evidence for this efficacy axis.
Why this is classified as D (25)
Repeated positive signals for liver enzymes, tissue injury, oxidative stress, and alcohol metabolism in ethanol-injured hepatocytes, HepG2 cells, and rats mean this is not a question-mark category with no efficacy literature. It is D for preclinical-only evidence because human randomized trials address other efficacy axes and no trial directly tested hangover, alcohol-related liver disease, or sustained liver-enzyme improvement. This yields D with 25 points; product standardization and safety are separate.
Counterpoint. Persistent AST or ALT elevation or fatty liver calls for alcohol reduction or abstinence, management of weight and metabolic risk, and evaluation for viral, medicine-related, and other causes. A Dendropanax product does not offset alcohol harm or create a safer drinking allowance.
Rejudgment record. New verdict — Applied the same preclinical-only D rule as verdict 870 because actual studies show improved AST, ALT, tissue injury, oxidative stress, and blood-alcohol surrogates in ethanol-injured hepatocytes, HepG2 cells, and rats, while no trial directly tested human hangover, alcohol-related liver disease, or sustained liver-enzyme outcomes
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Relief of hangover symptoms in humans | D | Improved blood alcohol and acetaldehyde came from rats, with no verified human hangover-symptom trial. |
| Improvement of alcohol-related liver injury in humans | D | Protection of liver histology and oxidative stress is preclinical in cells and rats, with no clinical outcome in patients with alcohol-related liver disease. |
| Improvement of alcohol-related human liver enzymes such as AST and ALT | D | AST and ALT improved in rats, but no direct human trial verified sustained liver-enzyme change. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Bae D et al. 2015 | Preclinical study in ethanol-injured hepatocytes and rats | 0 | Funding details were not confirmed in the accessible bibliographic and abstract record | Cell viability, reactive oxygen species, AST, ALT, malondialdehyde, antioxidant enzymes, CYP2E1, and blood alcohol | The aqueous leaf extract improved ethanol-induced cellular and rat liver injury, oxidative measures, and alcohol-metabolism markers. | Direct-ingredient preclinical alcohol-liver evidence |
| Eom T et al. 2020 | Extract dose study in alcohol-fed rats | 0 | Funding details were not confirmed in the accessible abstract record | Liver histology, AST, ALT, blood alcohol, acetaldehyde, antioxidant enzymes, and gut microbiota | Aqueous and ethanol leaf extracts improved selected liver-injury and alcohol-metabolism measures in a concentration-dependent manner. | Independent corroborating preclinical evidence |
| Jun JE et al. 2022 | Twelve-week randomized double-blind placebo-controlled human trial | 74 | Funding details were not confirmed in the accessible abstract record | Hemoglobin A1c, insulin resistance, blood pressure, lipids, body composition, and metabolic syndrome | The trial reported selected glycemic and blood-pressure findings but did not assess drinking, hangover, alcohol-related liver injury, or liver enzymes. | Human exposure and short-term safety context, not efficacy evidence for this claim |
Receipt — 3 References
All 3 cited sources were verified for existence at the original page (as of 2026-07-20).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-20 · Corrections: none
Cite this verdict
[Chamgap] Dendropanax morbiferus extract x hangover relief and improvement of alcohol-related liver injury and enzymes — Evidence Grade D·25. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/liver/dendropanax-morbiferus-hangover-alcoholic-liver/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.